Investigational Drug Information for Hetrombopag
✉ Email this page to a colleague
What is the drug development status for Hetrombopag?
Hetrombopag is an investigational drug.
There have been 24 clinical trials for Hetrombopag.
The most recent clinical trial was a Phase 1 trial, which was initiated on May 1st 2022.
The most common disease conditions in clinical trials are Thrombocytopenia, Anemia, Aplastic, and Purpura, Thrombocytopenic, Idiopathic. The leading clinical trial sponsors are Jiangsu HengRui Medicine Co., Ltd., Peking Union Medical College Hospital, and Yin Jie.
There are three US patents protecting this investigational drug and forty international patents.
Summary for Hetrombopag
| US Patents | 3 |
| International Patents | 40 |
| US Patent Applications | 10 |
| WIPO Patent Applications | 3 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 1 (2022-05-01) |
| Vendors | 4 |
Recent Clinical Trials for Hetrombopag
| Title | Sponsor | Phase |
|---|---|---|
| Hetrombopag for Lower-risk MDS With Thrombocytopenia: a Prospective，Open-label, Single-arm Study. | Tongji Hospital | Phase 2 |
| A Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Chemotherapy in Advanced Breast Cancer | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 |
| A Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Chemotherapy in Advanced Breast Cancer | Henan Cancer Hospital | Phase 2 |
Clinical Trial Summary for Hetrombopag
Top disease conditions for Hetrombopag
Top clinical trial sponsors for Hetrombopag
US Patents for Hetrombopag
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Hetrombopag | See Plans and Pricing | Bicyclo-substituted pyrazolon azo derivatives, preparation process and pharmaceutical use thereof | Jiangsu Hengrui Medicine Co. Ltd. (Jiangsu, CN) Shanghai Hengrui Pharmaceutical Co. Ltd. (Shanghai, CN) | See Plans and Pricing |
| Hetrombopag | See Plans and Pricing | Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof | Jiangsu Hengrui Medicine Co., Ltd. (CN) Shanghai Hengrui Pharmaceutical Co., Ltd. (CN) | See Plans and Pricing |
| Hetrombopag | See Plans and Pricing | Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof | Jiangsu Hengrui Medicine Co., Ltd. (CN) Shanghai Hengrui Pharmaceutical Co., Ltd. (CN) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Hetrombopag
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Hetrombopag | Australia | AU2009207966 | 2028-01-10 | See Plans and Pricing |
| Hetrombopag | Brazil | BRPI0907234 | 2028-01-10 | See Plans and Pricing |
| Hetrombopag | Canada | CA2711535 | 2028-01-10 | See Plans and Pricing |
| Hetrombopag | China | CN101481352 | 2028-01-10 | See Plans and Pricing |
| Hetrombopag | China | CN101679286 | 2028-01-10 | See Plans and Pricing |
| Hetrombopag | European Patent Office | EP2236500 | 2028-01-10 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
